Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Control Bionics Ltd. ( (AU:CBL) ) has shared an update.
Control Bionics Limited announced the resignation of its chairman, Dr. Samuel Straface, due to competing commitments. Damian Lismore, an independent director, has been appointed as interim non-executive chairman. This leadership change comes as the company continues to expand its market reach with innovative products like NeuroNode and NeuroStrip, positioning itself for growth in various sectors including health diagnostics and sports performance.
More about Control Bionics Ltd.
Control Bionics is a medical device company that develops technology to aid patients with communication difficulties due to conditions like Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Their core product, NeuroNode, is a wearable device that captures brain signals and integrates with eye gaze technology to facilitate computer interaction. They are also commercializing the NeuroStrip, a miniaturized EMG device for new markets such as health diagnostics and sports performance. The company operates in North America, Australia, Singapore, and Japan.
Average Trading Volume: 1,028,004
Technical Sentiment Signal: Buy
Current Market Cap: A$22.98M
For detailed information about CBL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “Losing the Console Race by Miles”: Microsoft Stock (NASDAQ:MSFT) Ticks Up as the Console Wars Gain a Bit of Clarity
- “…In 18 Months This is a $35,000 Truck” Tesla Stock (NASDAQ:TSLA) Surges With New Pricing Projections
- “Historic Union Busting”: Starbucks Stock (NASDAQ:SBUX) Slips as Strikes Gain Ground, Draw Congress Reps